Details

Autor(en) / Beteiligte

• Zhang, Jiang
• Schewe, Julia
• Li, Hanwei
• Makeschin, Marie-Christine
• Mahajan, Ujjwal M
• Gerbes, Alexander L
• Steib, Christian J

Titel

The effects of hepatic steatosis on thromboxane A 2 induced portal hypertension

Ist Teil von

• Gastroenterología y hepatología, 2019-11, Vol.42 (9), p.534

Ort / Verlag

Spain

Erscheinungsjahr

2019

Quelle

MEDLINE

Beschreibungen/Notizen

• AbstractIntroduction and aimThromboxane (TX) A 2 was identified as an important vasoconstrictor during Zymosan induced portal perfusion pressure (PP) increase. We aimed at investigating whether hepatic steatosis influences the extent of TXA 2-induced portal hypertension. Materials and methodsSprague–Dawley rats were randomly divided into control and steatosis (induced by the special diet) groups. PP and TXB 2 (stable degradation product of TXA 2) in the perfusate were measured after in situ liver perfusion with Zymosan (150 μg/ml, 40–46 min) or U46619 (TXA 2 analog, 0.1 μM/ml, 40–46 min). The number of Kupffer cell (KC) was measured by immunohistochemistry with CD163. ResultsZymosan induced more TXB 2 production and a higher PP increase in control group than in steatosis group despite more CD163 positive KCs in fatty livers. PP and TXB 2 efflux revealed a strong correlation in control group and a moderate correlation in steatosis group. Contrary to the effect of Zymosan, U46619 induced a much higher PP increase in steatosis group than in control group. ConclusionSevere steatosis increased number of KCs, however, PP increase and TXB 2 efflux caused by Zymosan infusion in fatty livers were lower than those in healthy livers. In contrast, TXA 2 analog caused higher PP increase in fatty livers. Targeting the more sensitive response to TXA 2 in fatty livers might be a potential therapy of severe steatosis.